Cellevate closed a rights issue on November 15. The company raised SEK 5 million which it will use to scale up its activities primarily in sales and marketing. The investment initiative is headed up by Tobias Ekman and Mats Leifland, and the consortium has a heavy background in industrial upscaling and financing issues. Other participants (all through companies) in this round are Peter Thulin, Peter Jhaveri, Magnus Stenberg, Joakim Leifland, Gustav Von Arnold, as well as VIG AB.
Cellevate is based in Lund and works with nanomaterials for applications in the life sciences. The company develops and commercializes new products to streamline biological basic biological research and drug development.
“We’re thrilled to see such strong interest and so many people who share our vision. The capital will help us to accelerate, but the main objective of this round has been to bring expertise and experience on board. We are pleased to have built a strong team of operational stakeholders and owners, which has now prepared us to take the company to the next level,” says CEO Maximilian Ottosson.
Cellevate is a members of SmiLe Incubator, a business incubator in the life sciences that helps entrepreneurs to commercialize their ideas by offering business advisory services, laboratories and networks. www.smileincubator.life